Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 6, 2021

Primary Completion Date

June 17, 2022

Study Completion Date

August 15, 2022

Conditions
Parkinson DiseaseDyskinesia, Drug-InducedDyskinesias
Interventions
DRUG

Dipraglurant

Oral 50mg and 100mg tablet

DRUG

Placebo

Oral matching placebo tablet

Trial Locations (41)

10029

Icahn School of Medicine at Mount Sinai, New York

11725

David L Kreitzman MD PC, Commack

19107

University of Pennsylvania, Philadelphia

23456

Sentara Neurology Specialists, Virginia Beach

30033

NeuroStudies.net, LLC - ClinEdge - PPDS, Decatur

30329

Emory University, Atlanta

30912

Augusta University, Augusta

32174

Neurology Associates of Ormond Beach, Ormond Beach

32806

AES - DRS - Synexus Clinical Research US, Inc. - Orlando, Orlando

32960

Geodyssey Research LLC, Vero Beach

33486

Parkinson's Disease and Movement Disorders Center of Boca Raton Inc, Boca Raton

33712

Suncoast Neuroscience Associates Inc, St. Petersburg

34471

Renstar Medical Research -21 NE 1st Ave, Ocala

37232

Vanderbilt University Medical Center, Nashville

43614

University of Toledo, Gardner-McMaster Parkinson Center, Toledo

44195

The Cleveland Clinic Foundation, Cleveland

46256

Josephson Wallack Munshower Neurology PC, Indianapolis

48824

Michigan State University, East Lansing

53705

University of Wisconsin Hospitals and Clinics, Madison

57105

Avera Medical Group, Sioux Falls

60612

Rush University Medical Center, Chicago

62702

Southern Illinois University School of Medicine, Springfield

66160

University of Kansas Medical Center, Kansas City

80113

Rocky Mountain Movement Disorders Center, Englewood

85004

Xenosciences Inc, Phoenix

90503

Pacific Neuroscience Institute, Torrance

92697

University of California Irvine Medical Center, Irvine

93710

Neuro-Pain Medical Center, Fresno

94304

Stanford Neuroscience Health Center, Palo Alto

98034

Evergreen Hospital Medical Center, Kirkland

06066

Chase Family Movement Disorders Center - Vernon, Vernon

33612-4799

University of South Florida, Tampa

48025-4334

Henry Ford Health System, Bingham Farms

08103

Cooper University Hospital, Camden

08901

Rutgers, the State University of New Jersey, New Brunswick

87106-2719

University of New Mexico Health Sciences Center, Albuquerque

43210-1267

The Ohio State University Wexner Medical Center, Columbus

19001-3816

Abington Neurologic Associates, Abington

78229-3901

UT Health Science Center, San Antonio, San Antonio

23502-3932

Meridian Clinical Research (Norfolk, Virginia), Norfolk

53226-0509

Froedtert and The Medical College of Wisconsin, Milwaukee

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Addex Pharma S.A.

INDUSTRY

NCT04857359 - Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy | Biotech Hunter | Biotech Hunter